The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.
Open accessAbstract
Rapamycin is a new antifungal antibiotic produced by Streptomyces hygroscopicus NRRL 5491. It was isolated from the mycelium by solvent extraction, purified by silica gel column chromatography and crystallized as a colorless solid which melts at 183 approximately to 185 degrees C and has the empirical formula C56H89NO14. From its characteristic ultraviolet absorption spectrum rapamycin can be classified as a triene. It is highly active against various Candida species, especially Candida albicans. Its activity is compared with that of amphotericin B, candicidin and nystatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Self-citation
Cited by
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Self-citationTargeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Lessons from natural molecules
Clardy, J., & Walsh, C. (2004) · Nature · doi:10.1038/nature03194 · Cited by 1,171
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP
Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996) · Science · doi:10.1126/science.273.5272.239 · Cited by 929
Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design
Babine, R. E., & Bender, S. L. (1997) · Chemical Reviews · doi:10.1021/cr960370z · Cited by 892
Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies
Dzau, V. J., Braun-Dullaeus, R. C., & Sedding, D. G. (2002) · Nature Medicine · doi:10.1038/nm1102-1249 · Cited by 831
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Sirolimus: its discovery, biological properties, and mechanism of action
Sehgal, S. N. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00211-2 · Cited by 779
Self-citationBierer, B. E., Mattila, P. S., Standaert, R. F., Herzenberg, L. A., Burakoff, S. J., Crabtree, G., & Schreiber, S. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9231 · Cited by 696
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
Self-citationIMMUNOPHARMACOLOGY OF RAPAMYCIN
Abraham, R. T., & Wiederrecht, G. J. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653
Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts
G�thel, S. F., & Marahiel, M. A. (1999) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180050299 · Cited by 647
MacDonald, A. S. (2001) · Transplantation · doi:10.1097/00007890-200101270-00019 · Cited by 621
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Tandem reactions, cascade sequences, and biomimetic strategies in total synthesis
Nicolaou, K. C., Montagnon, T., & Snyder, S. A. (2003) · Chemical Communications · doi:10.1039/b209440c · Cited by 614
Characterization of the FKBP·Rapamycin·FRB Ternary Complex
Banaszynski, L. A., Liu, C. W., & Wandless, T. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja043277y · Cited by 609
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Hidalgo, M., & Rowinsky, E. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204091 · Cited by 582
Dendritic cells: emerging pharmacological targets of immunosuppressive drugs
Hackstein, H., & Thomson, A. W. (2004) · Nature Reviews Immunology · doi:10.1038/nri1256 · Cited by 545
Fighting neurodegeneration with rapamycin: mechanistic insights
Bové, J., Martínez-Vicente, M., & Vila, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3068 · Cited by 525
Clinical Pharmacokinetics of Everolimus
Kirchner, G. I., Meier-Wiedenbach, I., & Manns, M. P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443020-00002 · Cited by 508
PI3K/Akt/mTOR pathway as a target for cancer therapy
Morgensztern, D., & McLeod, H. L. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000173476.67239.3b · Cited by 468
Rapamycin in transplantation: A review of the evidence
Saunders, R. N., Metcalfe, M. S., & Nicholson, M. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00460.x · Cited by 461
Bench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis
Marx, S. O., & Marks, A. R. (2001) · Circulation · doi:10.1161/01.cir.104.8.852 · Cited by 447
mTOR substrate phosphorylation in growth control
Battaglioni, S., Benjamin, D., Wälchli, M., Maier, T., & Hall, M. N. (2022) · Cell · doi:10.1016/j.cell.2022.04.013 · Cited by 434
Oxidative Cyclization in Natural Product Biosynthesis
Tang, M.-C., Zou, Y., Watanabe, K., Walsh, C. T., & Tang, Y. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00478 · Cited by 425
Mechanism of action of the immunosuppressant rapamycin
Dumont, F. J., & Su, Q. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02233-3 · Cited by 358
Vascular Smooth Muscle Cell Proliferation in Restenosis
Marx, S. O., Totary-Jain, H., & Marks, A. R. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.110.957332 · Cited by 354
Activity of rapamycin (AY-22,989) against transplanted tumors.
ENG, C. P., SEHGAL, S. N., & VEZINA, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 351
Self-citationImmunosuppressive drugs: the first 50 years and a glance forward
Allison, A. C. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00186-7 · Cited by 350
Peptidylproline cis‐trans‐isomerases: immunophilins
GALAT, A. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb18189.x · Cited by 343
Immunophilin-sensitive protein phosphatase action in cell signaling pathways
Schreiber, S. L. (1992) · Cell · doi:10.1016/0092-8674(92)90158-9 · Cited by 342
Law, J. W.-F., Ser, H.-L., Khan, T. M., Chuah, L.-H., Pusparajah, P., Chan, K.-G., Goh, B.-H., & Lee, L.-H. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00003 · Cited by 331
Clinical Pharmacokinetics of Sirolimus
Mahalati, K., & Kahan, B. D. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00002 · Cited by 302
Biosynthesis and attachment of novel bacterial polyketide synthase starter units
(2002) · Natural Product Reports · doi:10.1039/b003939j · Cited by 301
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Witzig, T. E., Reeder, C. B., LaPlant, B. R., Gupta, M., Johnston, P. B., Micallef, I. N., Porrata, L. F., Ansell, S. M., Colgan, J. P., Jacobsen, E. D., et al. (2011) · Leukemia · doi:10.1038/leu.2010.226 · Cited by 297
Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
MacDonald, A., Scarola, J., Burke, J. T., & Zimmerman, J. J. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)89027-x · Cited by 292
Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Huang, S., & Zhou, H. (2011) · Current Protein & Peptide Science · doi:10.2174/138920311795659407 · Cited by 270
Nicolaou, K. C., Hale, C. R. H., Nilewski, C., & Ioannidou, H. A. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35116a · Cited by 267
MTOR inhibitors in cancer therapy
Xie, J., Wang, X., & Proud, C. G. (2016) · F1000Research · doi:10.12688/f1000research.9207.1 · Cited by 266
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Biosynthesis of Erythromycin and Rapamycin
Staunton, J., & Wilkinson, B. (1997) · Chemical Reviews · doi:10.1021/cr9600316 · Cited by 260
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
Industrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides
Morris, R. E. (1992) · Transplantation Reviews · doi:10.1016/s0955-470x(10)80014-x · Cited by 253
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Stoica, L., Zhu, P. J., Huang, W., Zhou, H., Kozma, S. C., & Costa-Mattioli, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014715108 · Cited by 232
Chang, Z., & Heitman, J. (2019) · mBio · doi:10.1128/mbio.02579-19 · Cited by 202
“Furthermore, antifungals, including FK506 and rapamycin, both of which bind to FKBP12, are known to be produced by members of the bacterial genus Streptomyces, which are found in soil (37, 38).”
BackgroundRefined structure of the FKBP12–rapamycin–FRB ternary complex at 2.2 Å resolution
Liang, J., Choi, J., & Clardy, J. (1999) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998014747 · Cited by 148
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
Seto, B. (2012) · Clinical and Translational Medicine · doi:10.1186/2001-1326-1-29 · Cited by 149
Rapamycin-inspired macrocycles with new target specificity
Guo, Z., Hong, S. Y., Wang, J., Rehan, S., Liu, W., Peng, H., Das, M., Li, W., Bhat, S., Peiffer, B., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0187-4 · Cited by 120
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin
Chong, Z. Z., Shang, Y. C., Wang, S., & Maiese, K. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.001 · Cited by 119
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
The Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging
Zhang, Y., Zhang, J., & Wang, S. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101376 · Cited by 92
Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01658 · Cited by 72
Jung, W. S., Yoo, Y. J., Park, J. W., Park, S. R., Han, A. R., Ban, Y. H., Kim, E. J., Kim, E., & Yoon, Y. J. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3348-6 · Cited by 68
Specchio, N., Nabbout, R., Aronica, E., Auvin, S., Benvenuto, A., de Palma, L., Feucht, M., Jansen, F., Kotulska, K., Sarnat, H., et al. (2023) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2023.08.005 · Cited by 58
Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis
Franz, D. N., & Weiss, B. D. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0269-4 · Cited by 58
Wang, C. P., Chan, K. W., Schiksnis, R. A., Scatina, J., & Sisenwine, S. F. (1994) · Journal of Liquid Chromatography · doi:10.1080/10826079408013519 · Cited by 42
Castro-Falcón, G., Millán-Aguiñaga, N., Roullier, C., Jensen, P. R., & Hughes, C. C. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00598 · Cited by 29
(2015) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2015.04.03 · Cited by 24
Metadata
- Authors
- SEHGAL, S. N., BAKER, H., & VÉZINA, C.
- Venue
- The Journal of Antibiotics
- Published
- 1975
- Volume
- 28
- Issue
- 10
- Pages
- 727-732
- ISSN
- 0021-8820 (ISSN-L)
- 1881-1469
- OpenAlex
- W2626632314
- Cited by
- 947
- References
- 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.